TargetMol

BYAKANGELICIN

Product Code:
 
TAR-T5813
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5813-1mg1mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-1mL1 mL * 10 mM (in DMSO)£163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-10mg10mg£203.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-50mg50mg£455.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-100mg100mg£623.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BYAKANGELICIN,a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor,and is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.
CAS:
482-25-7
Formula:
C17H18O7
Molecular Weight:
334.32
Pathway:
Metabolism; Endocrinology/Hormones
Purity:
0.9986
SMILES:
COc1c2ccoc2c(OC[C@@H](O)C(C)(C)O)c2oc(=O)ccc12
Target:
Reductase

References

Shin K H , Lim S S , Kim D K . Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.[J]. Phytomedicine International Journal of Phytotherapy & Phytopharmacology, 1998, 5(2):121. Yang J , Luan X , Gui H , et al. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes[J]. British Journal of Pharmacology, 2010, 162(2):441-451.